Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients R Cervera, JC Piette, J Font, MA Khamashta, Y Shoenfeld, MT Camps, ... Arthritis & Rheumatism: Official Journal of the American College of …, 2002 | 2585 | 2002 |
Morbidity and mortality in systemic lupus erythematosus during a 10-year period: a comparison of early and late manifestations in a cohort of 1,000 patients R Cervera, MA Khamashta, J Font, GD Sebastiani, A Gil, P Lavilla, ... Medicine 82 (5), 299-308, 2003 | 1801 | 2003 |
Morbidity and mortality in the antiphospholipid syndrome during a 10-year period: a multicentre prospective study of 1000 patients R Cervera, R Serrano, GJ Pons-Estel, L Ceberio-Hualde, Y Shoenfeld, ... Annals of the rheumatic diseases 74 (6), 1011-1018, 2015 | 1128* | 2015 |
Morbidity and mortality in systemic lupus erythematosus during a 5-year period: a multicenter prospective study of 1,000 patients R Cervera, MA Khamashta, J Font, GD Sebastiani, A Gil, P Lavilla, ... Medicine 78 (3), 167-175, 1999 | 595 | 1999 |
Ixekizumab, an interleukin-17A specific monoclonal antibody, for the treatment of biologic-naive patients with active psoriatic arthritis: results from the 24-week randomised … PJ Mease, D van der Heijde, CT Ritchlin, M Okada, RS Cuchacovich, ... Annals of the rheumatic diseases 76 (1), 79-87, 2017 | 586 | 2017 |
Efficacy and safety of tofacitinib monotherapy, tofacitinib with methotrexate, and adalimumab with methotrexate in patients with rheumatoid arthritis (ORAL Strategy): a phase … R Fleischmann, E Mysler, S Hall, AJ Kivitz, RJ Moots, Z Luo, R DeMasi, ... The Lancet 390 (10093), 457-468, 2017 | 478 | 2017 |
Ixekizumab for the treatment of patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors: results from the 24-week randomised … P Nash, B Kirkham, M Okada, P Rahman, B Combe, GR Burmester, ... The Lancet 389 (10086), 2317-2327, 2017 | 446 | 2017 |
Immunochip analysis identifies multiple susceptibility loci for systemic sclerosis MD Mayes, L Bossini-Castillo, O Gorlova, JE Martin, X Zhou, WV Chen, ... The American Journal of Human Genetics 94 (1), 47-61, 2014 | 253 | 2014 |
Clinical outcomes of hospitalised patients with COVID-19 and chronic inflammatory and autoimmune rheumatic diseases: a multicentric matched cohort study JL Pablos, M Galindo, L Carmona, A Lledó, M Retuerto, R Blanco, ... Annals of the rheumatic diseases 79 (12), 1544-1549, 2020 | 246 | 2020 |
Efficacy and safety of epratuzumab in moderately to severely active systemic lupus erythematosus: results from two phase III randomized, double‐blind, placebo‐controlled trials MEB Clowse, DJ Wallace, RA Furie, MA Petri, MC Pike, P Leszczyński, ... Arthritis & rheumatology 69 (2), 362-375, 2017 | 228 | 2017 |
Systemic lupus erythematosus in Europe at the change of the millennium: lessons from the “Euro-Lupus Project” R Cervera Autoimmunity reviews 5 (3), 180-186, 2006 | 190 | 2006 |
Osteoarticular complications of brucellosis. JD Colmenero, JM Reguera, A Fernandez-Nebro, F Cabrera-Franquelo Annals of the rheumatic diseases 50 (1), 23-26, 1991 | 190 | 1991 |
A large-scale genetic analysis reveals a strong contribution of the HLA class II region to giant cell arteritis susceptibility FD Carmona, SL Mackie, JE Martín, JC Taylor, A Vaglio, S Eyre, ... The American Journal of Human Genetics 96 (4), 565-580, 2015 | 188 | 2015 |
Incidence, associated factors and clinical impact of severe infections in a large, multicentric cohort of patients with systemic lupus erythematosus Í Rúa-Figueroa, J López-Longo, M Galindo-Izquierdo, J Calvo-Alén, ... Seminars in arthritis and rheumatism 47 (1), 38-45, 2017 | 149 | 2017 |
Treatment of rheumatic inflammatory disease in 25 patients with secondary amyloidosis using tumor necrosis factor alpha antagonists A Fernández-Nebro, E Tomero, V Ortiz-Santamaría, MC Castro, A Olivé, ... The American journal of medicine 118 (5), 552-556, 2005 | 145 | 2005 |
Efficacy and safety of rituximab in the treatment of non-renal systemic lupus erythematosus: a systematic review T Cobo-Ibáñez, E Loza-Santamaría, JM Pego-Reigosa, AO Marqués, ... Seminars in arthritis and rheumatism 44 (2), 175-185, 2014 | 142 | 2014 |
Multicenter longitudinal study of B-lymphocyte depletion in refractory systemic lupus erythematosus: the LESIMAB study A Fernandez-Nebro, JLM De la Fuente, L Carreno, MG Izquierdo, ... Lupus 21 (10), 1063-1076, 2012 | 139 | 2012 |
Anti-neutrophil cytoplasmic antibodies in 566 European patients with systemic lupus erythematosus: prevalence, clinical associations and correlation with other autoantibodies … M Galeazzi, G Morozzi, GD Sebastiani, F Bellisai, R Marcolongo, ... Clinical and experimental rheumatology 16 (5), 541-546, 1998 | 137 | 1998 |
2014 update of the Consensus Statement of the Spanish Society of Rheumatology on the use of biological therapies in rheumatoid arthritis R Sanmartí, S García-Rodríguez, JM Álvaro-Gracia, JL Andreu, A Balsa, ... Reumatología Clínica (English Edition) 11 (5), 279-294, 2015 | 133* | 2015 |
Cardiovascular events in systemic lupus erythematosus: a nationwide study in Spain from the RELESSER registry A Fernandez-Nebro, Í Rúa-Figueroa, FJ Lopez-Longo, ... Medicine 94 (29), e1183, 2015 | 129 | 2015 |